- Home
- SWVL vs NRSN Comparison
SWVL vs NRSN Comparison
Compare SWVL & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- NRSN
- Stock Information
- Founded
- SWVL 2017
- NRSN 2017
- Country
- SWVL United Arab Emirates
- NRSN Israel
- Employees
- SWVL N/A
- NRSN N/A
- Industry
- SWVL Business Services
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- NRSN Health Care
- Exchange
- SWVL Nasdaq
- NRSN Nasdaq
- Market Cap
- SWVL 44.5M
- NRSN 51.1M
- IPO Year
- SWVL N/A
- NRSN 2021
- Fundamental
- Price
- SWVL $4.37
- NRSN $2.35
- Analyst Decision
- SWVL
- NRSN Buy
- Analyst Count
- SWVL 0
- NRSN 2
- Target Price
- SWVL N/A
- NRSN $14.00
- AVG Volume (30 Days)
- SWVL 6.5K
- NRSN 406.6K
- Earning Date
- SWVL 07-01-2025
- NRSN 07-01-2025
- Dividend Yield
- SWVL N/A
- NRSN N/A
- EPS Growth
- SWVL N/A
- NRSN N/A
- EPS
- SWVL N/A
- NRSN N/A
- Revenue
- SWVL $17,207,362.00
- NRSN N/A
- Revenue This Year
- SWVL N/A
- NRSN N/A
- Revenue Next Year
- SWVL N/A
- NRSN N/A
- P/E Ratio
- SWVL N/A
- NRSN N/A
- Revenue Growth
- SWVL N/A
- NRSN N/A
- 52 Week Low
- SWVL $2.40
- NRSN $0.51
- 52 Week High
- SWVL $8.25
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- SWVL 51.73
- NRSN 71.85
- Support Level
- SWVL $3.95
- NRSN $1.90
- Resistance Level
- SWVL $4.45
- NRSN $2.60
- Average True Range (ATR)
- SWVL 0.21
- NRSN 0.21
- MACD
- SWVL -0.08
- NRSN 0.03
- Stochastic Oscillator
- SWVL 44.68
- NRSN 75.49
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.